Integrative computational approaches in the quest for novel Ebolavirus therapeutics

While promising, translation of Ebola viral research remains limited by incomplete structural coverage, small and imbalanced datasets, and a gap between computational prediction and experimental validation. Hybrid <i>in silico</i> workflows are embedded within standardized, data-driven, and experimentally anchored pipelines, and are essential to bridge this gap. By uniting computational precision with laboratory validation, integrative strategies can accelerate the development of robust, deployable EBOV therapeutics and serve as a model for pandemic preparedness against other high-risk pathogens.